Autonomix, with a valuation of $70 million, is raising funds independently through Reg A+ crowdfunding. The company is developing a two-fold technology to detect malfunctioning neural signals and ablate nerves. Autonomix is opening up a world of possibilities in electrophysiology and working towards creating a simple procedure for pain management. The company is currently targeting pancreatic cancer pain and aims to target chronic pain, cardiovascular pain, and pulmonary diseases in the future. Dr. Robert Schwartz, Landy Roth, David Robins, and Dr. Robert Van Tassel founded Autonomix in 2014. The current crowdfunding campaign has a maximum target of $21.2 million. The campaign proceeds will be used for marketing, publishing, underwriting expenses, legal & accounting fees, and transfer agent.